<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04505189</url>
  </required_header>
  <id_info>
    <org_study_id>19HH5267</org_study_id>
    <nct_id>NCT04505189</nct_id>
  </id_info>
  <brief_title>Psilocybin as a Treatment for Anorexia Nervosa: A Pilot Study</brief_title>
  <official_title>Psilocybin as a Treatment for Anorexia Nervosa: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim of this study is to assess the acceptability and efficacy of treating&#xD;
      anorexia nervosa with psilocybin. The secondary aim of this study is to use Magnetic&#xD;
      Resonance Imaging (MRI) and Electroencephalography (EEG) to examine the neuronal&#xD;
      underpinnings of treatment with psilocybin in this patient group.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Anorexia nervosa is the most fatal of all psychiatric conditions. With the current paucity of&#xD;
      effective pharmacological and psychological treatments, and fewer than half of those&#xD;
      diagnosed making a full recovery, there is a great need for new treatment avenues to be&#xD;
      explored. For this study, we will recruit patients who have been suffering from a DSM-V&#xD;
      diagnosis of anorexia nervosa for 3 years or more, and who have found other forms of&#xD;
      treatment ineffective. Over a period of 6 weeks, participants who are deemed eligible at&#xD;
      screening will partake in 8 study visits, including three psilocybin dosing sessions with&#xD;
      varying doses. The maximum dose of psilocybin a participant will receive in a single session&#xD;
      is 25 mg. Across these 8 visits, there will also be 2 MRI scans, up to 5 EEG recordings and a&#xD;
      range of psychological measures (questionnaires and interviews). There will be a follow-up&#xD;
      period of 12 months following the final study visit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 28, 2021</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>All participants will receive 3 doses of psilocybin. The maximum dose a participant will receive in a single session is 25 mg.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Readiness and Motivation Questionnaire (RMQ)</measure>
    <time_frame>Baseline - Primary endpoint (6 weeks)</time_frame>
    <description>Increase in readiness and motivation to recover from baseline to primary endpoint, which will be related to long-term improvements in psychopathology.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Eating Disorder Examination (EDE)</measure>
    <time_frame>Baseline - Primary endpoint (6 weeks) - 6 month follow-up.</time_frame>
    <description>Decrease in eating disorder psychopathology.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Eating Disorder Examination Questionnaire (EDE-Q)</measure>
    <time_frame>Baseline - Primary endpoint (6 weeks) - 6 month follow-up.</time_frame>
    <description>Decrease in eating disorder psychopathology.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Functional Magnetic Resonance Imaging (fMRI)</measure>
    <time_frame>Baseline - Primary endpoint (6 weeks)</time_frame>
    <description>Changes in blood oxygen level dependent (BOLD) signal during rest and disorder relevant tasks.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Anorexia Nervosa</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Psilocybin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Psilocybin</intervention_name>
    <description>Psilocybin assisted psychotherapy</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Primary DSM-V diagnosis of Anorexia Nervosa&#xD;
&#xD;
          2. &gt;3 years of illness diagnosis&#xD;
&#xD;
          3. Current or past treatments have not been successful to maintain remission from&#xD;
             anorexia&#xD;
&#xD;
          4. Be in the care of a GP and specialist eating disorder team in the UK&#xD;
&#xD;
          5. Have a GP and specialist eating disorder team in the UK who can confirm diagnosis&#xD;
&#xD;
          6. Sufficiently competent in English and mental capacity to provide written informed&#xD;
             consent&#xD;
&#xD;
          7. BMI â‰¥15kg/m2 and medically stable&#xD;
&#xD;
          8. Capacity to consent&#xD;
&#xD;
          9. Agree to have us maintain contact with an identified next-of-kin for the duration of&#xD;
             the study&#xD;
&#xD;
         10. Agree to have us maintain contact with GP and/or specialist eating disorder team as&#xD;
             required, for the duration of the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Current or previously diagnosed psychotic disorder&#xD;
&#xD;
          2. Immediate family member with a diagnosed psychotic disorder&#xD;
&#xD;
          3. Unstable physical condition e.g., rapid weight loss &gt; 2kg in the prior month&#xD;
&#xD;
          4. Abnormal serum electrolytes, raised cardiac enzymes, hepatic or renal dysfunction&#xD;
&#xD;
          5. MRI or EEG contraindications&#xD;
&#xD;
          6. A history of laxative abuse in the last 3 months (more than twice a week for 3 months)&#xD;
&#xD;
          7. History of serious suicide attempts or presence of a suicide/ serious self-harm risk&#xD;
             at screening&#xD;
&#xD;
          8. Currently an involuntary patient&#xD;
&#xD;
          9. Emotionally unstable personality, history of mania, or other psychiatric problem that&#xD;
             the screening clinician feels may jeopardise the therapeutic alliance and/or safe&#xD;
             exposure to psilocybin&#xD;
&#xD;
         10. Blood or needle phobia&#xD;
&#xD;
         11. Positive pregnancy test at screening or during the study, or woman who are&#xD;
             breastfeeding&#xD;
&#xD;
         12. If sexually active, participants who lack appropriate contraceptive measures&#xD;
&#xD;
         13. Drug or alcohol dependence within the last 6 months&#xD;
&#xD;
         14. No email access&#xD;
&#xD;
         15. Patients presenting with abnormal QT interval prolongation at screening or with a&#xD;
             history of this (QTc at screening above 470ms)&#xD;
&#xD;
         16. Patients who are currently, or have recently (within 3 months) been enrolled in&#xD;
             another CTIMP.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Meg J Spriggs, PhD</last_name>
    <phone>+44 7538223146</phone>
    <email>panorexia.trial@imperial.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Imperial College Hammersmith campus</name>
      <address>
        <city>London</city>
        <zip>W12 0NN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meg Spriggs, Dr</last_name>
      <email>panorexia.trial@imperial.ac.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 30, 2020</study_first_submitted>
  <study_first_submitted_qc>August 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2020</study_first_posted>
  <last_update_submitted>August 24, 2021</last_update_submitted>
  <last_update_submitted_qc>August 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anorexia</mesh_term>
    <mesh_term>Anorexia Nervosa</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psilocybin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

